RenovoRx, Inc. (RNXT) stock
RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30124% above fair value
$1.04−0.12 (-10.34%)
Close on Nov 13, 2026Market cap $46.93MP/E –Yield –
RenovoRx price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
RenovoRx's price to sales ratio was 27.9× on Nov 11, 2026.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 27.9× | – |
See a number that looks wrong?